Is Xeris Biopharma Holdings, Inc. overvalued or undervalued?

As of 13 August 2018, the valuation grade for Xeris Biopharma Holdings, Inc. moved from does not qualify to risky, indicating a significant change in its risk profile. The company is currently assessed as overvalued, given its negative financial metrics. Key ratios include a Price to Book Value of -20.88, an EV to EBIT of -40.50, and an EV to EBITDA of -91.67, all of which highlight the company's struggles in generating positive returns.
In comparison to its peers, Xeris Biopharma's P/E ratio is notably worse at -15.77 compared to uniQure NV at -3.60 and Nuvation Bio, Inc. at -3.21, both of which also fall under the risky category. The company's recent stock performance shows a 119.91% return over the past year, significantly outpacing the S&P 500's 10.26% return, yet this does not mitigate the valuation concerns stemming from its negative earnings and high debt metrics.